Zymeworks is releasing a new drug, ZW25, to treat HER2-expressing Gastroesophageal Adenocarcinoma. The phase one trials for this drug done, and the data for the trials will be released on January 15, 2021. For optimal gains, buy a week in advance and sell the day of the data release. Again, the data will be released 11:30-12:15 EST on January 15, 2021 . Like and...
Despite a 75% move in 2019 there is still plenty of room to run, indicators are still not oversold and volume remains very high.
Momentum shows no sign of slowing down
Continual upside call buying in the option market.
Promising trial data expected in cancer fighting Drug program.
Moving averages are perfectly formed and fanning out as strength continues....
After a initial drop on the news of the $175million offering the stock did drop but has since rebounded and extended the gains and the momentum looks to continues with $25 as a reasonable short term target.
Proceeds of the offering will go toward expanding development of ZW25 (as a single agent and in combination), expanding developing of ZW49 through an ongoing...
This Biotechnology company which has several positive analysis from experts of the sector has a quite interesting chart.
I believe that we are entering in its Wave 5 and my target Price is set at much higher levels.
Above $16 I expect it to gain thrust.
What I like here are the following:
- It already gave 3 Waves and number 3 was quite impressive.
- Wave 4 ended...
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
NYSE
